BPC-157 vs GHK-Cu at a glance
Neither compound has a published head-to-head trial against the other. What follows is a side-by-side reading of two separate research literatures, not a controlled comparison study.
| Property | BPC-157 | GHK-Cu |
|---|---|---|
| Structure | 15-amino-acid pentadecapeptide | Tripeptide (Gly-His-Lys) bound to Cu2+ |
| Origin | Sequence from human gastric juice protein, described by Sikiric's group in the early 1990s | Isolated from human plasma by Pickart in 1973 |
| Primary mechanism | VEGFR2 activation, Akt-eNOS signaling | Copper delivery to lysyl oxidase, SOD, and MMP/TIMP regulation |
| Main tissue focus in literature | GI tract, tendon, muscle, bone, nerve | Dermal fibroblasts, skin, wound beds |
| Typical research route | Intraperitoneal, subcutaneous, oral (stable in gastric acid) | Topical in most published wound studies |
| Human trial status | Phase I safety trial; Phase II colitis trial with unpublished full dataset | No registered RCT for wound healing as of 2026 |
Two different repair mechanisms
BPC-157 research points to a vascular mechanism. A 2017 study by Hsieh et al. in the Journal of Molecular Medicine (Hsieh et al. 2017, in vitro and rat hind limb ischemia model) found that BPC-157 increases VEGFR2 expression and internalization in vascular endothelial cells, activating the downstream VEGFR2-Akt-eNOS pathway. Treated rats recovered blood flow faster after induced hind limb ischemia, with higher vessel density on histology than controls.
That angiogenic signal is context-dependent rather than constant. A 2009 study by Brcic et al. in the Journal of Physiology and Pharmacology (Brcic et al. 2009, rat muscle and tendon crush/transection model) found no angiogenic effect when BPC-157 was applied to cells in culture, yet observed elevated VEGF expression and vessel markers in the same tissue types when the peptide was given in vivo during active healing. Separately, a 2014 study by Chang et al. in Molecules (Chang et al. 2014, rat Achilles tendon fibroblasts) reported that BPC-157 raised growth hormone receptor expression in tendon fibroblasts and, when growth hormone was added afterward, boosted proliferation through JAK2 activation.
GHK-Cu research does not center on vascular signaling. Its role is copper transport. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for Cu/Zn superoxide dismutase, a cellular antioxidant. A 1988 study by Maquart et al. in FEBS Letters (Maquart et al. 1988, in vitro fibroblast cultures) found that GHK-Cu stimulated collagen synthesis in fibroblasts at concentrations between 10-12 and 10-9 M, independent of any change in cell count. A follow-up study by Simeon et al. in Life Sciences (Simeon et al. 2000, in vitro fibroblast cultures) showed GHK-Cu also raises MMP-2 alongside TIMP-1 and TIMP-2, meaning it drives both breakdown of damaged collagen and the brakes that keep that breakdown from running unchecked.
What the animal evidence shows, and where it disagrees
BPC-157's animal literature spans a wide range of tissue types: gastric ulcer models, bowel anastomosis healing, Achilles tendon detachment, quadriceps reattachment, bone fracture, and spinal cord injury, almost entirely in rats. The consistent caveat across independent reviews is that more than 80% of published BPC-157 studies originate from Sikiric's laboratory at the University of Zagreb Medical School, which limits how confidently the reported effect sizes generalize outside that research group's conditions.
GHK-Cu's animal literature is narrower, concentrated on skin and wound beds, but it is not uniformly positive. Rabbit and rodent wound models generally show improved contraction, granulation tissue, and vessel density with topical GHK-Cu. A 2013 study by Parker et al. in Otolaryngology-Head and Neck Surgery (Parker et al. 2013, irradiated rat dorsal flap model) tested the compound under harsher conditions and found no benefit: treated flaps showed no difference in vessel count, vessel area, or VEGF expression compared to controls, and the mean ischemic area was larger in the treated group (5.0 cm² vs 3.8 cm²). That result suggests GHK-Cu's benefit in standard wound models may not extend to tissue already compromised by radiation damage, a distinction that matters for anyone reading the compound's evidence base as uniformly favorable.
Human trial status compared
BPC-157 has moved further through the human trial pipeline than GHK-Cu, at least on paper. A Phase I safety study in healthy volunteers, run by the Croatian company Pliva, was presented at Digestive Disease Week 2003 and described the compound as well tolerated. A subsequent Phase II trial (PL-14736) tested a BPC-157 enema in mild-to-moderate ulcerative colitis in a multicenter, randomized, double-blind, placebo-controlled design. Conference reports described positive results, but the complete dataset was never published in a peer-reviewed journal, so the Phase II findings cannot be independently verified. No Phase III trial has been registered for BPC-157 in any indication as of 2026.
GHK-Cu has no equivalent trial record for wound healing. The most cited human data point, a 12-week study comparing topical GHK-Cu, vitamin C cream, and retinoic acid on thigh skin, reported collagen production improvements in 70% of GHK-Cu subjects versus 50% for vitamin C and 40% for retinoic acid. That figure appears in review articles by Pickart and colleagues rather than in a registered trial with a public protocol, and it has not been independently replicated. For the full research and mechanism writeups on each compound, see the BPC-157 research overview and the GHK-Cu research overview.
Practical considerations for research use
Both compounds are supplied as lyophilized powder and require reconstitution before use in a research protocol. Storage rules are the same for each: keep the sealed lyophilized powder at -20°C away from light, and once reconstituted in bacteriostatic water, refrigerate at 2 to 8°C. The full reconstitution steps, including bacteriostatic water ratios and sterile technique, are covered in the peptide reconstitution guide; syringe volume and concentration math for either compound can be run through the dosing calculator.
Administration route differs across the published literature for each compound. BPC-157 has been given by intraperitoneal, subcutaneous, and oral routes in animal studies, since the peptide is stable in gastric acid. GHK-Cu's wound-healing studies are almost entirely topical; the systemic and injectable literature on GHK-Cu is thinner than for BPC-157. Researchers combining both compounds in a protocol should note that no published study has tested BPC-157 and GHK-Cu together, so any assumption about a combined effect is an extrapolation from two separate bodies of research, not a tested outcome.
Zurich Biotech carries both compounds, listed under the BPC-157 + TB-500 line and the GHK-Cu line, each shipped with HPLC purity testing and a Certificate of Analysis. In Indonesia's climate, ambient temperatures above 28°C and relative humidity above 70% are the main threat to either peptide once reconstituted; the lyophilized peptide storage guide covers cold-chain setups that hold up in Bali and Jakarta conditions.